Displaying 31–38 of 38 news results
Jan 18, 2018 Industry News
The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today launched a new program that offers financial support for individuals with inherited retinal diseases.
Jan 9, 2018 The Foundation in the News
AN EMERGING, vision-restoring gene therapy for a devastating retinal disease is poised for Food and Drug Administration (FDA) approval. If it gets the regulatory nod, it will be the first gene therapy to receive FDA approval for the eye or an inherited condition.
Oct 12, 2017 Industry News
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
Apr 13, 2016 Foundation News
David Brint has been elected Chairman, effective July 1, 2016. Brint succeeds co-founder and current Chairman, Gordon Gund, who will remain a member of the Board of Directors and will continue to be actively involved in the Foundation’s Research Oversight Committee
Oct 1, 2015 The Foundation in the News
In a recent interview with CNBC’ s Brian Sullivan, during a tech-investor conference in Nantucket, Gordon explained why this is such a crucial time in retinal-research history.
Jan 14, 2014 Foundation News
Five of six participants in the initial study group have sustained vision improvements in their treated eyes in dim settings.
Dec 12, 2013 The Foundation in the News
The Foundation’s chairman and co-founder, Gordon Gund is interviewed on Forbes.com
May 8, 2008 Foundation News